ClinicalTrials.gg
RecruitingNCT07551492Updated Sep 8, 2026

A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease

A Phase 3 interventional study of HRS9531 and HRS9531 placebo in Atherosclerotic Cardiovascular Disease, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9,262
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies in Atherosclerosis with a site in China — 36 open to participants now, 48 under way, 11 of them phase 3. Atherosclerosis · China.

Planned enrollment
13th of 79
9,262 · median 200
Started
2026
with 14 others
Phase 3
18 of 113
4 open now
Primary completion
2031-05
later than 47 of 47 live
Registered
104th of 113
by date

Among the 113 studies in Atherosclerosis with a site in China, this one is the 13th largest by planned enrollment of the 79 interventional ones that give a count, is one of 15 that started in 2026, is one of 18 in phase 3, reaches primary completion later than 47 of the 47 other live ones, and was the 104th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

36 of the 113 studies in Atherosclerosis with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Atherosclerosis with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the impact of HRS9531 on major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease. This study adopts an event-driven design and ends when the target number of the primary endpoint event is reached.

03

Conditions studied

  • Atherosclerotic Cardiovascular Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with atherosclerotic cardiovascular disease (ASCVD)
  2. The (BMI) at the time of screening was ≥24.0 kg/m ². Patients with type 2 diabetes have a BMI of ≥22.0 kg/m ²

Exclusion criteria

Exclusion Criteria:

  1. Screening for myocardial infarction, acute decompensated heart failure, hospitalization due to heart failure, unstable angina pectoris, stroke or , coronary revascularization, atrial flutter/fibrillation ablation, valve repair/replacement, carotid or peripheral artery recanalization within 30 days prior to the screening
  2. Severe hypoglycemic events or recurrent hypoglycemic events occurred within one month before screening
  3. When screening, there are proliferative retinopathy or macular degeneration requiring acute treatment, painful diabetic neuropathy, diabetic foot ulcers
  4. Coronary revascularization, atrial flutter/fibrillation ablation, valve repair/replacement, and carotid or peripheral artery recanalization are planned to be performed during the trial
  5. Those with a history of acute or chronic pancreatitis, acute cholecystitis, or symptomatic or treatment-requiring gallbladder diseases
  6. Any malignant tumor of the organ system has occurred within the past five years, regardless of whether there is evidence of local recurrence or , except for cured local cutaneous basal cell carcinoma and cervical carcinoma in situ
  7. Pregnant or lactating women, or participants with fertility who are unwilling to take effective measures
  8. Those who have had any previous conditions that affected gastric emptying or have undergone gastrointestinal surgery
  9. Diagnosed or suspected as type 1 diabetes, special type diabetes or secondary diabetes
  10. Acute complications of diabetes occurred within one month before screening
  11. There are endocrine diseases that may significantly affect weight
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
9,262 participants (estimated)

Study arms

  • Experimental
    HRS9531 Group A

    Drug: HRS9531

  • Placebo comparator
    HRS9531 placebo Group B

    Drug: HRS9531 placebo

Interventions

  • HRS9531 Dose 1 , subcutaneous injection

  • DrugHRS9531 placebo

    HRS9531 placebo Dose 1, subcutaneous injection

06

What researchers measure

Primary outcomes

  1. The time from randomization to the first occurrence of the MACE-3 composite endpoint

    Time frame: approximately up to 61 months of treatment

Secondary outcomes

  1. Time to the first occurrence of the MACE-4 composite endpoint

    Time frame: approximately up to 61 months of treatment

  2. Time to the first occurrence of the extended MACE composite endpoint

    Time frame: approximately up to 61 months of treatment

  3. Time to the first occurrence of the composite endpoint of heart failure;

    Time frame: approximately up to 61 months of treatment

  4. Time to the first occurrence of the composite endpoint of kidney disease;

    Time frame: approximately up to 61 months of treatment

  5. Time to the first occurrence of the composite endpoint of major adverse limb events;

    Time frame: approximately up to 61 months of treatment;

  6. Time when each component event of the MACE-3 composite endpoint occurred for the first time

    Time frame: approximately up to 61 months of treatment;

  7. Time when all-cause death occurs;

    Time frame: approximately up to 61 months of treatment;

  8. Time to the first hospitalization due to heart failure;

    Time frame: approximately up to 61 months of treatment;

  9. Time to the first emergency heart failure visit;

    Time frame: approximately up to 61 months of treatment;

  10. Time when the first persistent eGFR decreased by ≥50% from baseline;

    Time frame: approximately up to 61 months of treatment;

  11. Time when persistent eGFR < 15 mL/min/1.73m2 occurred for the first time;

    Time frame: approximately up to 61 months of treatment;

  12. Time to first entering chronic renal replacement therapy (dialysis or kidney transplantation) ;

    Time frame: approximately up to 61 months of treatment;

  13. The time when renal death occurs;

    Time frame: approximately up to 61 months of treatment;

  14. Time to hospitalization for the first occurrence of acute limb ischemia;

    Time frame: approximately up to 61 months of treatment;

  15. Time to hospitalization for the first occurrence of unplanned chronic limb ischemia;

    Time frame: approximately up to 61 months of treatment

  16. Incidence and severity of adverse events ;

    Time frame: Approximately 61 months

  17. Change from baseline in body weight;

    Time frame: From randomization to 104 weeks

  18. Change from baseline in waistline;

    Time frame: From randomization to 104 weeks

  19. Change from baseline in glycosylated hemoglobin;

    Time frame: From randomization to 104 weeks

  20. Change from baseline in blood lipid parameter;

    Time frame: From randomization to 104 weeks

  21. Change from baseline in blood pressure;

    Time frame: From randomization to 104 weeks

  22. Change from baseline in glomerular filtration;

    Time frame: From randomization to 104 weeks

  23. Change from baseline in Uric Acid;

    Time frame: From randomization to 104 weeks

  24. Change from baseline in hsCRP;

    Time frame: From randomization to 104 weeks

  25. The time to the first unplanned revascularization event

    Time frame: approximately up to 61 months of treatment;

  26. Time when the first persistent eGFR decreased by ≥40% from baseline;

    Time frame: approximately up to 61 months of treatment

07

Study locations

1 of 1 sites recruiting
  • Fuwai Hospital, CAMS&PUMC
    Beijing, Beijing Municipality 100037, China
    Recruiting
    • Kefei Dou · Principal investigator
    • Xiao Wang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2031, 59 months after the start.

Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's planned 59 months is above that.

Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
Apr 24, 2026
StartActual
May 29, 2026
Primary completionEst.
May 24, 2031
CompletionEst.
Jun 28, 2031
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07551492
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
May 29, 2026
Primary completion
May 24, 2031 (estimated)
Completion
Jun 28, 2031 (estimated)
Last update
Sep 8, 2026

Study contacts

Sheng Qi
Contact
Sheng.qi@hengrui.com
+8613482562074
Kefei Dou
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital
Xiao Wang
study director · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion